Evidence map›Paper›PMID 24999331›Full record

ArticleFrontiers in pharmacology2014

Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry.

Charles Reese, Rebecca Lee, Michael Bonner, Beth Perry, Jonathan Heywood, Richard M Silver, Elena Tourkina, Richard P Visconti, Stanley Hoffman

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Circulating Fibrocytes: Cellular Mediators of Tissue Fibrosis.International journal of molecular sciences · 2026
    Review
  2. CD45+/ Col I+ Fibrocytes: Major source of collagen in the fibrotic lung, but not in passaged fibroblast cultures.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sca-1European journal of immunology · 2018
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Charles ReeseDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA.
Rebecca LeeDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA.
Michael BonnerDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA.
Beth PerryDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA.
Jonathan HeywoodDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA.
Richard M SilverDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA.
Elena TourkinaDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA ; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina Charleston, SC, USA.
Richard P ViscontiDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina Charleston, SC, USA.
Stanley HoffmanDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina Charleston, SC, USA ; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina Charleston, SC, USA.
Medical University of South Carolina · US

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4M
SC COBRE for Developmentally Based Cardiovascular DiseasesP30GM103342 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MARKWALD, ROGER R · 2012 to 2016
$5.5M
Caveolin-1 Regulates Monocyte-Fibrocyte Lineage Cell Functions via CXCR4R01AR062078 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TOURKINA, ELENA · 2012 to 2016
$1.6M
NCATS NIH HHS UL1 TR000062NIAMS NIH HHS R01 AR062078NIGMS NIH HHS P30 GM103342
6 · The paper itself

Abstract

Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs. Given their origin, they or their precursors must be circulating cells before recruitment into target tissues. While most previous studies focused on circulating fibrocytes, here we focus on the fibrocyte phenotype in fibrotic tissue. The study's relevance to human disease is heightened by use of a model in which bleomycin is delivered systemically, recapitulating several features of human scleroderma including multi-organ fibrosis not observed when bleomycin is delivered directly into the lungs. Using flow cytometry, we find in the fibrotic lung a large population of CD45(high) fibrocytes (called Region I) rarely found in vehicle-treated control mice. A second population of CD45+ fibrocytes (called Region II) is observed in both control and fibrotic lung. The level of CD45 in circulating fibrocytes is far lower than in either Region I or II lung fibrocytes. The chemokine receptors CXCR4 and CCR5 are expressed at higher levels in Region I than in Region II and are present at very low levels in all other lung cells including CD45+/collagen I- leucocytes. The collagen chaperone HSP47 is present at similar high levels in both Regions I and II, but at a higher level in fibrotic lung than in control lung. There is also a major population of HSP47(high)/CD45- cells in fibrotic lung not present in control lung. CD44 is present at higher levels in Region I than in Region II and at much lower levels in all other cells including CD45+/collagen I- leucocytes. When lung fibrosis is inhibited by restoring caveolin-1 activity using a caveolin-1 scaffolding domain peptide (CSD), a strong correlation is observed between fibrocyte number and fibrosis score. In summary, the distinctive phenotype of fibrotic lung fibrocytes suggests that fibrocyte differentiation occurs primarily within the target organ.

Indexed as

caveolin-1CCR5CD44CD45collagenCXCR4HSP47scleroderma

Identifiers

PMID24999331
PMCPMC4058709
OpenAlexW2089374427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.